A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion), based off the original product Remicade (infliximab, Janssen). Biosimilars promise significant cost savings for patients, but the unavoidable differences between innovator and copycat biologics raise questions regarding product interchangeability. In this study, Remicade and Remsima were examined by native mass spectrometry, ion mobility, and quantitative peptide mapping. The levels of oxidation, deamidation, and mutation of individual amino acids were remarkably similar. We found different levels of C-terminal truncation, soluble protein aggregates, and glycation that all likely have a limited clinical impact. Importantly, we identified more than 25 glycoforms for each product and observed glycoform population differences, with afucosylated glycans accounting for 19.7% of Remicade and 13.2% of Remsima glycoforms, which translated into a 2-fold reduction in the level of FcγIIIa receptor binding for Remsima. While this difference was acknowledged in Remsima regulatory filings, our glycoform analysis and receptor binding results appear to be somewhat different from the published values, likely because of methodological differences between laboratories and improved glycoform identification by our laboratory using a peptide map-based method. Our mass spectrometry-based analysis provides rapid and robust analytical information vital for biosimilar development. We have demonstrated the utility of our multiple-attribute monitoring workflow using the model mAbs Remicade and Remsima and have provided a template for analysis of future mAb biosimilars.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Byonic: Advanced Peptide and Protein Identification Software
Bern, M., Kil, Y. J., & Becker, C. (2012) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1320s40 · Cited by 659
Self-citation
Cited by
Collision induced unfolding of isolated proteins in the gas phase: past, present, and future
Dixit, S. M., Polasky, D. A., & Ruotolo, B. T. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.11.010 · Cited by 235
Self-citationGiorgetti, J., D’Atri, V., Canonge, J., Lechner, A., Guillarme, D., Colas, O., Wagner-Rousset, E., Beck, A., Leize-Wagner, E., & François, Y.-N. (2018) · Talanta · doi:10.1016/j.talanta.2017.09.083 · Cited by 65
“published an important work describing a multidimensional analytical comparison of infliximab-Remicade® and the biosimilar infliximab-Remsima® [30].”
BackgroundIon mobility in the pharmaceutical industry: an established biophysical technique or still niche?
Campuzano, I. D., & Lippens, J. L. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.11.008 · Cited by 42
Metadata
- Authors
- Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., Saveliev, S., Hosfield, C. M., Urh, M., Carlson, E., Becker, C., Tolbert, T. J., Schwendeman, S. P., Ruotolo, B. T., & Schwendeman, A.
- Venue
- Analytical Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-04-17
- Volume
- 89
- Issue
- 9
- Pages
- 4838-4846
- ISSN
- 0003-2700 (ISSN-L)
- 1520-6882
- OpenAlex
- W2597473030
- Cited by
- 75
- References
- 2
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. https://app.cochat.ai/papers/10.1021/acs.analchem.6b04436
- The paper
- Pisupati, K., Tian, Y., Okbazghi, S., Benet, A., Ackermann, R., Ford, M., Saveliev, S., Hosfield, C. M., Urh, M., Carlson, E., Becker, C., Tolbert, T. J., Schwendeman, S. P., Ruotolo, B. T., & Schwendeman, A. (2017). A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.6b04436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.